Skip to main content
ONCY
NASDAQ Life Sciences

Oncolytics' Pelareorep Shows 3-4x Longer Response in Colorectal Cancer, Eyes Accelerated FDA Approval

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$0.889
Mkt Cap
$101.043M
52W Low
$0.326
52W High
$1.51
52W Position info
173% above low
Off High info
41% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

ONCY has more than doubled off its 52-week low of $0.326.

Summary

Oncolytics Biotech reported highly positive durability and response rate data from its REO 022 study for pelareorep in second-line RAS-mutant MSS colorectal cancer. The study demonstrated a 19.5-month median duration of response, representing a significant 3-4x improvement over historical benchmarks of 4-6 months, and an objective response rate of 33%, tripling the standard of care. This follows a recent 8-K filing on the same day that also highlighted this positive data, and an earlier 8-K from April 27th regarding alignment with the FDA on a pivotal study design. For a clinical-stage biotech with a modest market cap, these results are highly material, indicating substantial clinical benefit in a difficult-to-treat patient population. The company is actively engaging with the FDA to discuss a potential accelerated approval pathway, which could be a major catalyst. Investors should monitor further updates on FDA discussions and the progress of the ongoing randomized Phase 2 study.

At the time of this announcement, ONCY was trading at $0.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $101M. The 52-week trading range was $0.33 to $1.51. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

ONCY - Latest Insights

ONCY
Nov 13, 2026, 4:16 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.370
Real-time Price: $0.3636 info
Change: -$0.0064 (-2%) info
Market Cap: $47.179M info
ONCY
Oct 27, 2026, 10:33 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $0.462
Real-time Price: $0.3636 info
Change: -$0.0984 (-21%) info
Market Cap: $47.179M info
ONCY
Sep 28, 2026, 9:32 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.6831
Real-time Price: $0.3636 info
Change: -$0.3195 (-47%) info
Market Cap: $47.179M info
ONCY
Sep 28, 2026, 9:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.6827
Real-time Price: $0.3636 info
Change: -$0.3191 (-47%) info
Market Cap: $47.179M info
ONCY
Aug 18, 2026, 9:05 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $0.8328
Real-time Price: $0.3636 info
Change: -$0.4692 (-56%) info
Market Cap: $47.179M info